M&A Deal Summary |
|
|---|---|
| Date | 2003-11-20 |
| Target | Oculex Pharmaceuticals |
| Sector | Life Science |
| Buyer(s) | Allergan |
| Sellers(s) |
Aisling Capital
Bay City Capital |
| Deal Type | Add-on Acquisition |
| Deal Value | 230M USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1948 |
| Sector | Life Science |
| Employees | 11,400 |
Allergan, Inc. is a pharmaceutical company. Allergan's products include ophthalmic pharmaceuticals, dermatology products, and neurological products.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 14 |
| Sector: Life Science M&A | 1 of 5 |
| Type: Add-on Acquisition M&A Deals | 1 of 13 |
| State: California M&A | 1 of 8 |
| Country: United States M&A | 1 of 14 |
| Year: 2003 M&A | 1 of 1 |
| Size (of disclosed) | 6 of 10 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2006-03-23 |
Inamed
Santa Barbara, California, United States Inamed Corp. manufactures and develops healthcare products in US. |
Buy | $3.3B |
| Category | Private Equity Firm |
|---|---|
| Founded | 2000 |
| PE ASSETS | 1.8B USD |
| Size | Large |
| Type | Sector Focused |
Aisling Capital is a private investment firm focused on opportunities in the healthcare and medical technology sectors. The Firm specifically looks to invest in companies developing and commercializing innovative healthcare products, services, and technologies. Aisling Capital looks to commit $20 to $50 million per investment and prefers to be the lead investor. Aisling will consider investing in both public and private companies. Aisling Capital raised its first fund in 2000. The Firm is based in New York City.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 41 |
| Sector: Life Science M&A | 2 of 32 |
| Type: Add-on Acquisition M&A Deals | 2 of 24 |
| State: California M&A | 1 of 13 |
| Country: United States M&A | 2 of 41 |
| Year: 2003 M&A | 1 of 2 |
| Size (of disclosed) | 10 of 12 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2002-08-01 |
Oculex Pharmaceuticals
Sunnyvale, California, United States Oculex Pharmaceuticals, Inc. is an Ophthalmic drug delivery company. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2003-12-21 |
Esperion Therapeutics
Plymouth, Michigan, United States Development stage biotechnology company focused on cardiovascular drugs. Drug discovery and development company focused on therapies that prevent, treat and reverse cardiovascular and metabolic diseases. |
Sell | - |
| Category | Venture Capital Firm |
|---|---|
| Founded | 1997 |
| PE ASSETS | 1.3B USD |
| Size | Large |
| Type | Sector Focused |
Bay City Capital LLC was established in 1997 as an equal partnership between The Craves Group and certain Pritzker family business interests for the purpose of managing investment funds in the life sciences industry. Bay City looks for opportunities at all stages of development in biopharmaceuticals, drug discovery, medical devices and diagnostics. Bay City Capital is based in San Francisco, California.
| DEAL STATS | # |
|---|---|
| Overall | 12 of 63 |
| Sector: Life Science M&A | 9 of 46 |
| Type: Add-on Acquisition M&A Deals | 6 of 31 |
| State: California M&A | 5 of 33 |
| Country: United States M&A | 12 of 60 |
| Year: 2003 M&A | 4 of 4 |
| Size (of disclosed) | 9 of 18 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2003-11-06 |
Pharmion
Boulder, Colorado, United States Pharmion Corporation is a global oncology company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza®, a DNA demethylating agent. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2004-06-22 |
Senomyx
San Diego, California, United States Senomyx is a producer of proprietary flavor and fragrance molecules for use in a wide range of consumer products. Senomyx’s integrated technology platform combines an enhanced understanding of the biology of taste and smell with many of the same technologies and advancements that pharmaceutical companies have recently begun using to more efficiently discover new medicines. Senomyx was founded in 1998 and is based in San Diego, California. |
Sell | - |
